

## Additions and Corrections

---

2004, Volume 47

**Dennis R. Compton, Shubin Sheng, Kathryn E. Carlson, Natalie A. Rebacz, In Young Lee, Benita S. Katzenellenbogen, and John A. Katzenellenbogen\***: Pyrazolo[1,5-*a*]pyrimidines: Estrogen Receptor Ligands Possessing Estrogen Receptor  $\beta$  Antagonist Activity.

Page 5877. In Table 1, the correct values of ER $\alpha$  and ER $\beta$  for compound **24b** are  $0.01 \pm 0.001$  and  $0.36 \pm 0.01$ , respectively.

JM058162Z

10.1021/jm058162z

Published on Web 02/05/2005

**Thomas W. von Geldern,\* Noah Tu, Philip R. Kym, James T. Link, Hwan-Soo Jae, Chunqiu Lai, Theresa Apelqvist, Patrik Rhonnstad, Lars Hagberg, Konrad Koehler, Marlena Grynfarb, Annika Goos-Nilsson, Johnny Sandberg, Marie Österlund, Tomas Barkhem, Marie Höglund, Jiahong Wang, Steven Fung, Denise Wilcox, Phong Nguyen, Clarissa Jakob, Charles Hutchins, Mathias Färnegårdh, Björn Kauppi, Lars Öhman, and Peer B. Jacobson**: Liver-Selective Glucocorticoid Antagonists: A Novel Treatment for Type 2 Diabetes.

Page 4223. The caption of Figure 7 incorrectly suggests that Sprague-Dawley rats were used in studies of HPA activation. Studies of HPA activation were performed using CD-1 mice (as described everywhere else in the manuscript).

JM058170F

10.1021/jm058170f

Published on Web 03/03/2005